Blog
RSS FeedPosted by Michael Wonder on 22 Oct 2025
Updated information about Pharmac’s priority lists (September 2025)
21 October 2025 - Pharmac’s Pūahoaho Report provides the latest information about applications for medicines, vaccines, and related products that we’ve ...
Posted by Michael Wonder on 20 Oct 2025
PHARMAC proposes greater transparency for medicine funding decisions
20 October 2025 - PHARMAC is proposing changes to bring greater transparency and clarity to how medicine funding applications are ...
Posted by Michael Wonder on 17 Oct 2025
Health Economics Methods Advisory Group releases draft report: asssessing treatment benefits in health technology assessment decision-making
9 October 2025 - Public comment period now open until 30 October 2025. ...
Posted by Michael Wonder on 09 Oct 2025
Why the Government must urgently raise the NICE cost effectiveness threshold
7 October 2025 - NICE plays an important role in determining whether new medicines will be funded for NHS patients ...
Posted by Michael Wonder on 08 Oct 2025
Britain prepares NHS drug spending hike to stave off Trump tariffs
8 October 2025 - The UK Government has drawn up proposals to increase the amount the National Health Service pays ...
Posted by Michael Wonder on 24 Sep 2025
FDA use of real world evidence in regulatory decision-making
22 September 2025 - The FDA has a long history of using real world data and real-world evidence to monitor and ...
Posted by Michael Wonder on 16 Sep 2025
The use of real world evidence among health care payers: a scoping review
12 September 2025 - Real world evidence is increasingly used to assess and make regulatory decisions on health technologies. However, its ...
Posted by Michael Wonder on 05 Aug 2025
Health technology assessment, again: a transparent, evidence-based approach for CMS drug price negotiations
4 August 2025 - The CMS can now negotiate the prices of a set of drugs that represent significant Medicare expenditures. ...
Posted by Michael Wonder on 16 Jul 2025
FDA embraces radical transparency by publishing complete response letters
10 July 2025 - The US FDA today published more than 200 decision letters, known as complete response letters. ...
Posted by Michael Wonder on 18 Jun 2025
PHARMAC declines inactive medicine applications
18 June 2025 - PHARMAC has declined 48 inactive funding applications so that it is clearer what medicines are currently ...
Posted by Michael Wonder on 20 May 2025
Redefining value assessment and healthcare funding priorities for medicines: the journey to patient-centric decision making in APAC – a systematic literature review
14 May 2025 - This study explored patient involvement in health care decision-making in the Asia-Pacific region by identifying roles and ...
Posted by Michael Wonder on 27 Apr 2025
The role and value of real-world evidence in health technology decision-making in France, Germany, Italy, Spain, and the UK: insights on external control arms
22 April 2025 - Real-world evidence is increasingly used and accepted by health technology assessment (HTA) bodies as supportive evidence ...
Posted by Michael Wonder on 03 Apr 2025
Real-world evidence to support health technology assessment and payer decision making: is it now or never?
31 March 2025 - The aim of this policy article is twofold: (i) to provide a summary and update of recent ...
Posted by Michael Wonder on 20 Mar 2025
Health Economics Methods Advisory Group selects first area for study: assessing treatment benefits appropriate to consider in HTA decision-making
18 March 2025 - The US based ICER, England’s NICE and Canada’s Drug Agency have selected the first research topic ...
Posted by Michael Wonder on 17 Feb 2025
Unravelling the association between uncertainties in model-based economic analysis and funding recommendations of medicines in Australia
14 February 2025 - Health technology assessment is used extensively by the PBAC to inform medicine funding recommendations in Australia. ...